GlassScriptPhysician profile
Daniel Lee Learned
NPI 1033406780
$48,627.79
in general payments reported to CMS, 2019-2025
15 companies · $8,943 in 2025
The $8,943 reported for 2025 was more than what 90% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $385 · 2021: $3,390 · 2022: $536 · 2023: $13K · 2024: $9,485 · 2025: $8,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,000 · Travel and Lodging: $3,405 · Food and Beverage: $2,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,290.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,000.00 |
| Travel and Lodging | $3,405.21 |
| Food and Beverage | $2,763.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $16,927.06 | 2024-2025 | Eylea Hd |
| Alimera Sciences, INC. | $7,722.37 | 2019-2024 | Iluvien, Yutiq |
| Genentech, INC. | $7,040.21 | 2023 | Vabysmo |
| Genentech USA, INC. | $6,428.51 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Alcon Vision LLC | $6,215.14 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $2,129.48 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $962.02 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $460.23 | 2022-2025 | Syfovre |
| Abbvie INC. | $257.98 | 2022-2025 | |
| Astellas Pharma US INC | $201.39 | 2023-2025 | Izervay |
| Allergan, INC. | $165.42 | 2019-2021 | |
| Boston Scientific Corporation | $36.99 | 2024 | |
| Biogen, INC. | $29.20 | 2022-2023 | |
| Harrow Eye, LLC | $27.89 | 2025 | Iheezo |
| Eyepoint US, INC. | $23.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Learned listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.